Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan, L., Wang, J., Tanizaki, J., Huang, Z., Aref, A.R., Rusan, M., Zhu, S.J., Zhang, Y., Ercan, D., Liao, R.G., Capelletti, M., Zhou, W., Hur, W., Kim, N., Sim, T., Gaudet, S., Barbie, D.A., Yeh, J.R., Yun, C.H., Hammerman, P.S., Mohammadi, M., Janne, P.A., Gray, N.S.(2014) Proc Natl Acad Sci U S A 111: E4869-E4877
- PubMed: 25349422 
- DOI: 10.1073/pnas.1403438111
- Primary Citation of Related Structures:  
4QQC, 4R5S, 4R6V - PubMed Abstract: 
The human FGF receptors (FGFRs) play critical roles in various human cancers, and several FGFR inhibitors are currently under clinical investigation. Resistance usually results from selection for mutant kinases that are impervious to the action of the drug or from up-regulation of compensatory signaling pathways ...